NERV
Minerva Neurosciences, IncstockNASDAQ
minerva neurosciences, inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of a portfolio of product candidates for the treatment of central nervous system diseases. its lead product candidate is roluperidone, which is in phase iii clinical trial, a compound for the treatment of schizophrenia. the company is also developing seltorexant that has completed phase iib clinical trial for treating insomnia and major depressive disorders; and min-301, which is in pre-clinical trial, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of parkinson's disease. minerva neurosciences, inc. has a license agreement with mitsubishi tanabe pharma corporation for the development and commercialization of the roluperidone worldwide, excluding asia; and co-development and license agreement with janssen pharmaceutica, n.v. for the development of seltorexant. the company was formerly known as cyrenaic pharmaceuticals, inc. and changed its
| Period | Price | Date | Change | Beta |
|---|---|---|---|---|
| 1W | 2.38 | 2026-11-12 | -10.50% | 2.004 |
| 1M | 2.32 | 2026-10-19 | -8.19% | 2.336 |
| 3M | 4.79 | 2026-08-19 | -55.53% | 2.302 |
| 6M | 4.36 | 2026-05-19 | -51.15% | 1.918 |
| 1Y | 4.30 | 2025-11-19 | -50.47% | 1.742 |
| 2Y | 2.10 | 2024-11-19 | +1.43% | — |
| 5Y | 8.96 | 2021-11-19 | -76.23% | 0.286 |
Minerva Neurosciences, Inc (NASDAQ:NERV) stock price today is $2.13, and today's volume is 119,805. NERV is down 2.294% today. The 30 day average volume is 184,653. NERV market cap is $106.15M with 49.84M shares outstanding.
